GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alar Pharmaceuticals Inc (ROCO:6785) » Definitions » Capex-to-Revenue

Alar Pharmaceuticals (ROCO:6785) Capex-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Alar Pharmaceuticals Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Alar Pharmaceuticals's Capital Expenditure for the three months ended in Dec. 2024 was NT$1.54 Mil. Its Revenue for the three months ended in Dec. 2024 was NT$0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Alar Pharmaceuticals Capex-to-Revenue Historical Data

The historical data trend for Alar Pharmaceuticals's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alar Pharmaceuticals Capex-to-Revenue Chart

Alar Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Revenue
Get a 7-Day Free Trial 0.64 - 1.42 0.01 0.21

Alar Pharmaceuticals Quarterly Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.18 -

Competitive Comparison of Alar Pharmaceuticals's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Alar Pharmaceuticals's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alar Pharmaceuticals's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alar Pharmaceuticals's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Alar Pharmaceuticals's Capex-to-Revenue falls into.


;
;

Alar Pharmaceuticals Capex-to-Revenue Calculation

Alar Pharmaceuticals's Capex-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-1.233) / 5.817
=0.21

Alar Pharmaceuticals's Capex-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (1.543) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alar Pharmaceuticals  (ROCO:6785) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Alar Pharmaceuticals Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Alar Pharmaceuticals's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Alar Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 32, Keya Road, 5th Floor, Daya District, Taichung, TWN, 407
Alar Pharmaceuticals Inc is a drug development company. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. These chronic diseases not only cause long-term burdens to the patients and their families but also consume huge social costs.

Alar Pharmaceuticals Headlines

No Headlines